Acute cardiac care & resuscitationMechanistic study
Cardiogenic shock complicating peripartum cardiomyopathy benefits from combination therapy with levosimendan and bromocriptine
- Mechanistic study
- PPCM mouse model (cardiomyocyte-specific STAT3 knockout)
- German PPCM registry
Authors' conclusion
Thus, the combination therapy with LS and BR seems to be a safe and potentially beneficial therapeutic concept for the treatment of PPCM patients with CS.
Study context
- Population
- PPCM mouse model (STAT3 CKO) and PPCM patients with cardiogenic shock from the German PPCM registryregistry patients with cardiogenic shock (CS)
- Participants
- 17 participants
- Comparison
- Levosimendan alone vs levosimendan plus bromocriptine
- Levosimendan (LS) + bromocriptine (BR)n = 17
Main finding
As reported in the abstract
Cardiac function and mortality (PPCM mouse model); acute-phase survival and LVEF (registry patients with CS)
| Group | Value | LVEF at 3-month follow-up (registry) |
|---|---|---|
| LS + BR | 40 ± 19 % | 40 ± 19% |
Original publication
Cardiogenic shock complicating peripartum cardiomyopathy benefits from combination therapy with levosimendan and bromocriptine. Eur J Heart Fail. Published 21 January 2026. doi:10.1093/ejhf/xuag002
Summarised from the published abstract; every number is checked against it